| Christopher T Crosby, DPM | |
|
3545 Highway 17, Suite 200, Murrells Inlet, SC 29576-5113 | |
| (843) 294-1941 | |
| (843) 294-1945 |
| Full Name | Christopher T Crosby |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 23 Years |
| Location | 3545 Highway 17, Murrells Inlet, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780608521 | NPI | - | NPPES |
| PD5667 | Medicaid | SC | |
| 371480687 | Other | SC | TAX ID |
| P00194318 | Other | SC | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 566 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Conway Medical Center | Conway, SC | Hospital |
| Tidelands Waccamaw Community Hospital | Murrells inlet, SC | Hospital |
| Mcleod Loris Hospital | Loris, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthosc Llc | 8022370030 | 88 |
News Archive
Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association's Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events in those over 65 years of age, and a reduction in cerebrocardiovascular deaths.
Centinel Spine, Inc., a market leader in the development, manufacture and distribution of Integrated Interbody Fusion™ devices, today announced a record 41.8% revenue increase during the 4th quarter, 2010, vs. 3rd quarter, 2010. Also, during the 4th quarter, 2010, Centinel achieved a record setting 32.5% gain vs. the same period in 2009.
Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.
Globally, an estimated 10 million people develop tuberculosis (TB) each year and the disease remains a leading cause of death from a single infectious agent. Standard short-course anti-TB treatment still requires a regimen of at least six months of antimicrobial drugs, and drug-resistant TB is an increasing public health threat.
Cancer diagnostics company Biomoda, Inc. today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.
› Verified 7 days ago
| Provider Name | Orthosc Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861902728 PECOS PAC ID: 8022370030 Enrollment ID: O20180501000455 |
News Archive
Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association's Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events in those over 65 years of age, and a reduction in cerebrocardiovascular deaths.
Centinel Spine, Inc., a market leader in the development, manufacture and distribution of Integrated Interbody Fusion™ devices, today announced a record 41.8% revenue increase during the 4th quarter, 2010, vs. 3rd quarter, 2010. Also, during the 4th quarter, 2010, Centinel achieved a record setting 32.5% gain vs. the same period in 2009.
Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.
Globally, an estimated 10 million people develop tuberculosis (TB) each year and the disease remains a leading cause of death from a single infectious agent. Standard short-course anti-TB treatment still requires a regimen of at least six months of antimicrobial drugs, and drug-resistant TB is an increasing public health threat.
Cancer diagnostics company Biomoda, Inc. today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher T Crosby, DPM 210 Village Center Blvd Ste 140, Myrtle Beach, SC 29579-6706 Ph: (843) 353-3460 | Christopher T Crosby, DPM 3545 Highway 17, Suite 200, Murrells Inlet, SC 29576-5113 Ph: (843) 294-1941 |
News Archive
Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association's Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events in those over 65 years of age, and a reduction in cerebrocardiovascular deaths.
Centinel Spine, Inc., a market leader in the development, manufacture and distribution of Integrated Interbody Fusion™ devices, today announced a record 41.8% revenue increase during the 4th quarter, 2010, vs. 3rd quarter, 2010. Also, during the 4th quarter, 2010, Centinel achieved a record setting 32.5% gain vs. the same period in 2009.
Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.
Globally, an estimated 10 million people develop tuberculosis (TB) each year and the disease remains a leading cause of death from a single infectious agent. Standard short-course anti-TB treatment still requires a regimen of at least six months of antimicrobial drugs, and drug-resistant TB is an increasing public health threat.
Cancer diagnostics company Biomoda, Inc. today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.
› Verified 7 days ago
South Carolina Podiatric Physicians And Surgeons Group, Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 912 Inlet Square Dr, Murrells Inlet, SC 29576 Phone: 843-347-3334 Fax: 843-431-2786 | |
Dunes Podiatry Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 11945 Grandhaven Dr, Suite G, Murrells Inlet, SC 29576 Phone: 843-357-3762 Fax: 843-357-3772 | |
Myers Podiatry Clinic Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 912 Inlet Square Dr, Myers Podiatry Clinic, Murrells Inlet, SC 29576 Phone: 843-347-3334 | |
Dr. Amy Lynne Wisdo, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 11945 Grandhaven Dr, Suite G, Murrells Inlet, SC 29576 Phone: 843-357-3762 Fax: 843-357-3772 |